Valuation dashboard for 10x Genomics, Inc. (TXG) with P/E N/A, P/B 15.39, EV/EBITDA 427.97 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific.
Analysis Summary
10x Genomics, Inc. reported revenue of $642.8M in the most recent fiscal year, growing at a 5-year CAGR of 16.6%.
Trailing-twelve-month margins: gross margin 70.0%, operating margin -14.3%, net margin -12.2%.
At the current price of $90.04, TXG has negative trailing earnings (P/E not meaningful) and an ROE of -9.33%. Market capitalisation stands at $11.4B, placing it among large-cap names.
Balance sheet quality for TXG: current ratio of 4.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 15.39 |
| EV / EBITDA | 427.97 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-9.38 |
| vs Current Price | -110.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| TXG | 10x Genomics, Inc. | $11.4B | 15.39 | -9.3% | |
| SDGR | Schrödinger, Inc. | $2.3B | 6.88 | -16.4% | |
| GRDN | Guardian Pharmacy Services, Inc. | $2.7B | 40.36 | 10.93 | 23.9% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.2B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $128.1B | 29.38 | 6.21 | 21.2% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $78.8B | 17.35 | 2.37 | 13.8% |
| REGN | Regeneron Pharmaceuticals, Inc. | $75.7B | 17.55 | 2.40 | 14.4% |
| MRNA | Moderna, Inc. | $75.4B | 11.13 | -39.2% |
Price
| Price | $90.04 |
| Market Cap | $11.4B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -9.33% |
| Return on Invested Capital | -9.57% |
| Return on Assets | -7.29% |
| Gross Margin | 70.03% |
| Operating Margin | -14.33% |
| Net Margin | -12.18% |
Related companies: CERT · GRDN · JANX · NUVB · OMCL · OMDA · PGNY
Explore sector: Healthcare · Biotechnology
More sections of TXG: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks